382 related articles for article (PubMed ID: 32931884)
1. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
2. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
4. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
Boichuk S; Galembikova A; Syuzov K; Dunaev P; Bikinieva F; Aukhadieva A; Zykova S; Igidov N; Gankova K; Novikova M; Kopnin P
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641324
[TBL] [Abstract][Full Text] [Related]
5. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.
Lin S; Du T; Zhang J; Wu D; Tian H; Zhang K; Jiang L; Lu D; Sheng L; Li Y; Ji M; Chen X; Xu H
J Med Chem; 2022 Dec; 65(24):16372-16391. PubMed ID: 36511661
[TBL] [Abstract][Full Text] [Related]
7. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
Duan Y; Liu W; Tian L; Mao Y; Song C
Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
[TBL] [Abstract][Full Text] [Related]
8. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
[TBL] [Abstract][Full Text] [Related]
9. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
10. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
Mahmud F; Deng S; Chen H; Miller DD; Li W
Cancer Lett; 2020 Dec; 495():76-88. PubMed ID: 32920198
[TBL] [Abstract][Full Text] [Related]
11. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
[TBL] [Abstract][Full Text] [Related]
12. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
Deng S; Banerjee S; Chen H; Pochampally S; Wang Y; Yun MK; White SW; Parmar K; Meibohm B; Hartman KL; Wu Z; Miller DD; Li W
Cancer Lett; 2023 Feb; 555():216046. PubMed ID: 36596380
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent microtubule-destabilizing agents targeting for colchicine site by virtual screening, biological evaluation, and molecular dynamics simulation.
Zhang H; Luo QQ; Hu ML; Wang N; Qi HZ; Zhang HR; Ding L
Eur J Pharm Sci; 2023 Jan; 180():106340. PubMed ID: 36435355
[TBL] [Abstract][Full Text] [Related]
14. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
15. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.
Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP
J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319
[TBL] [Abstract][Full Text] [Related]
17. Quinolin-6-Yloxyacetamides Are Microtubule Destabilizing Agents That Bind to the Colchicine Site of Tubulin.
Sharma A; Sáez-Calvo G; Olieric N; de Asís Balaguer F; Barasoain I; Lamberth C; Díaz JF; Steinmetz MO
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640209
[TBL] [Abstract][Full Text] [Related]
18. SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines.
Yan W; Yang T; Yang J; Wang T; Yu Y; Wang Y; Chen Q; Bai P; Li D; Ye H; Qiu Q; Zhou Y; Hu Y; Yang S; Wei Y; Li W; Chen L
Cell Physiol Biochem; 2018; 47(2):489-504. PubMed ID: 29794416
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in research of colchicine binding site inhibitors and their interaction modes with tubulin.
Sun K; Sun Z; Zhao F; Shan G; Meng Q
Future Med Chem; 2021 May; 13(9):839-858. PubMed ID: 33821673
[TBL] [Abstract][Full Text] [Related]
20. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
